FNY Managed Accounts’s Jazz Pharmaceuticals JAZZ Stock Holding History

FNY Managed Accounts’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-60	Closed	-$9K	–	640
2017 Q2	$9K	Buy	+60	New	+$9.18K	0.09%	124
2016 Q4	–	Sell	-1,681	Closed	-$204K	–	155
2016 Q3	$204K	Buy	+1,681	New	+$227K	0.17%	98

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FNY Managed Accounts's JAZZ Position: Q3 2017 in Review

FNY Managed Accounts sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 60 shares — an estimated $9K sold.

FNY Managed Accounts first reported a position in JAZZ in Q3 2016 and held it in 2 quarters. The position peaked at $204K in Q3 2016. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

FNY Managed Accounts reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
FNY Managed Accounts sold 60 Jazz Pharmaceuticals shares in Q3 2017, an estimated $9K.
FNY Managed Accounts first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 2 quarters.
FNY Managed Accounts's Jazz Pharmaceuticals position peaked at $204K in Q3 2016.
303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on FNY Managed Accounts's 13F filing for Q3 2017, filed 9 Nov 2017.